Safety
OESOPHAGEAL SQUAMOUS CELL CARCINOMA, ADVERSE EVENT
In Part A and Part B, the median number of cycles of treatment with cisplatin, 5‐FU, durvalumab, and tremelimumab completed was 4.0. The median (range) total treatment durations were 105.0 (24–161) days for cisplatin, 106.5 (24–166) days for 5‐FU, 123.5 (38–293) days for durvalumab, and 112.0 (38–129) days for tremelimumab.All patients experienced ≥1 AE (Table Summary of AEs in the ESCC Cohort.Abbreviations: 5‐FU, 5‐fluorouracil; AE, adverse event; ESCC, esophageal squamous cell carcinoma.As assessed by the investigator.Seven (43.8%) patients experienced ≥1 AESI (Table 